Biomarker discovery could lead to urine test for early stage pancreatic cancer
the ONA take:
A three-protein signature that can both identify the most common form of pancreatic cancer at an early stage and distinguish it from chronic pancreatitis has been found by a team of researchers at Barts Cancer Institute, Queen Mary University of London. The discovery could lead to a novel test for screening people at high risk using a urine sample.
Urine samples from patients with pancreatic cancer were found to have higher levels of LYVE1, REG1A, and TFF1, compared with samples from healthy patients; patients with chronic pancreatitis has significantly lower levels of the proteins than those with cancer.
The three proteins were selected for closer examination based on biological information and performance in statistical analysis.
Combined, they form a robust panel that can detect stages I-II pancreatic cancer with over 90% accuracy. Furthermore, using urine, an inert and less complex fluid than blood, is advantageous in that obtaining samples is noninvasive and can be done repeatedly.
The biomarker panel has good specificity and sensitivity. Pancreatic cancer is diagnosed in more than 80% of patients with the disease after it has already spread, significantly reducing eligibility for curative treatment options.
The researchers are hopeful that a simple, inexpensive test can be developed for use in the clinic within the next few years.
A three-protein signature can identify the most common form of pancreatic cancer at an early stage.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|